Hostname: page-component-76d6cb85b7-mgxrv Total loading time: 0 Render date: 2026-07-22T19:51:50.163Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Momen et al. “Demographic and Clinical Characteristics of Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults”

Published online by Cambridge University Press:  10 April 2026

Ilia Poliakov Open the ORCID record for Ilia Poliakov [Opens in a new window]
Ilia Poliakov*
Affiliation:
Neurology, University of Saskatchewan College of Medicine, Canada
*
Corresponding author: Ilia Poliakov; Email: iliapoliakov@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Momen, AI, Freedman, MS, Fadda, G, et al. Demographic and clinical characteristics of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder in Canadian adults. Can J Neurol Sci. 2026. (in press).10.1017/cjn.2026.10539CrossRefGoogle ScholarPubMed
Hor, JY, Asgari, N, Nakashima, I, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol. 2020;11:501. doi: 10.3389/fneur.2020.00501.CrossRefGoogle ScholarPubMed
Jarius, S, Aktas, O, Ayzenberg, I, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol. 2023;270(7):3341–68. doi: 10.1007/s00415-023-11634-0.CrossRefGoogle Scholar
Pekmezovic, T, Jovicevic, V, Andabaka, M, et al. Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: Population-based registry data. J Neurol. 2024;271(12):7525–36. doi: 10.1007/s00415-024-12698-2.CrossRefGoogle ScholarPubMed
Pandit, L, Asgari, N, Apiwattanakul, M, et al. GJCF international clinical consortium & biorepository for neuromyelitis optica. Demographic and clinical features of neuromyelitis optica: A review. Mult Scler. 2015;21(7):845–53. doi: 10.1177/1352458515572406.CrossRefGoogle Scholar
Tahara, M, Oeda, T, Okada, K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298–306. doi: 10.1016/S1474-4422(20)30066-1.CrossRefGoogle ScholarPubMed